G. Oner Et Al. , "Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy," WORLD JOURNAL OF SURGICAL ONCOLOGY , vol.19, no.1, 2021
Oner, G. Et Al. 2021. Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. WORLD JOURNAL OF SURGICAL ONCOLOGY , vol.19, no.1 .
Oner, G., Onder, S., Karatay, H., Ak, N., Tukenmez, M., Muslumanoglu, M., ... Igci, A.(2021). Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. WORLD JOURNAL OF SURGICAL ONCOLOGY , vol.19, no.1.
Oner, Gizem Et Al. "Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy," WORLD JOURNAL OF SURGICAL ONCOLOGY , vol.19, no.1, 2021
Oner, Gizem Et Al. "Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy." WORLD JOURNAL OF SURGICAL ONCOLOGY , vol.19, no.1, 2021
Oner, G. Et Al. (2021) . "Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy." WORLD JOURNAL OF SURGICAL ONCOLOGY , vol.19, no.1.
@article{article, author={Gizem ÖNER Et Al. }, title={Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy}, journal={WORLD JOURNAL OF SURGICAL ONCOLOGY}, year=2021}